Home
Einar Svarstad's picture

Einar Svarstad

Adjunct Professor
  • E-mailEinar.Svarstad@uib.no
  • Phone+47 55 97 29 79
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2020. The changing landscape of Fabry disease. Journal of the American Society of Nephrology. 569-576.
  • 2020. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. Journal of the American Society of Nephrology. 865-875.
  • 2019. Developing nephrology services in low income countries: A case of Tanzania. BMC Nephrology. 1-9.
  • 2018. Low birth weight associates with glomerular area in young male IgA nephropathy patients. BMC Nephrology. 1-10.
  • 2018. In vivo detection of chronic kidney disease using tissue deformation fields from dynamic MR imaging. IEEE Transactions on Biomedical Engineering. 1779-1790.
  • 2017. Pathomechanisms of renal Fabry disease. Cell and Tissue Research. 53-62.
  • 2017. Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry. Lupus. 881-885.
  • 2017. Long-term dose-dependent agalsidase effects on kidney histology in fabry disease. American Society of Nephrology. Clinical Journal. 1470-1479.
  • 2017. Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. Pediatric nephrology (Berlin, West). 1-14.
  • 2017. Bedside stereomicroscopy of Fabry kidney biopsies: An easily available method for diagnosis and assessment of sphingolipid deposits. Nephron. 13-21.
  • 2016. The variation in high sensitive cardiac troponin concentration during haemodialysis treatment is not similar to the biological variation observed in stable end stage renal disease patients. Scandinavian Journal of Clinical and Laboratory Investigation. 645-652.
  • 2016. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrology, Dialysis and Transplantation. 807-813.
  • 2016. Quantifcation of single-kidney function and volume in living kidney donors using dynamic contrast-enhanced MRI. American Journal of Roentgenology. 1022-1030.
  • 2016. Polyvinylpyrrolidone induced artefactual prolongation of activated partial thromboplastin times in intravenous drug users with renal failure. Journal of Thrombosis and Haemostasis. 936-939.
  • 2016. One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. PLOS ONE.
  • 2016. Low birth weight and risk of progression to end stage renal disease in IgA nephropathy - A retrospective registry-based cohort study. PLOS ONE.
  • 2016. Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. Pediatric nephrology (Berlin, West). 311-320.
  • 2016. Familial Factors, Low Birth Weight, and Development of ESRD: A Nationwide Registry Study. American Journal of Kidney Diseases. 601-608.
  • 2016. End stage renal disease predicts increased risk of death in first degree relatives in the Norwegian population. PLOS ONE.
  • 2016. Dynamic contrast-enhanced MRI measurement of renal function in healthy participants. Acta Radiologica. 748-757.
  • 2015. Use of 3D DCE-MRI for the estimation of renal perfusion and glomerular filtration rate: An intrasubject comparison of FLASH and KWIC with a comprehensive framework for evaluation. American Journal of Roentgenology. W273-W281.
  • 2015. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. Orphanet Journal of Rare Diseases. 1-10.
  • 2015. Global collaboration bears fruit: Tanzania report. Kidney International. 1211-1214.
  • 2015. Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria. Nephron. 16-21.
  • 2015. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. Molecular Genetics and Metabolism. 242-247.
  • 2015. Addition of eGFR and age improves the prognostic absolute renal risk-model in 1,134 norwegian patients with IgA nephropathy. American Journal of Nephrology. 210-219.
  • 2014. Weekly and 90-minute biological variations in cardiac troponin T and cardiac troponin I in hemodialysis patients and healthy controls. Clinical Chemistry. 838-847.
  • 2014. Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Reports. 83-90.
  • 2014. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLOS ONE.
  • 2014. Familial clustering of ESRD in the Norwegian population. American Society of Nephrology. Clinical Journal. 1692-1700.
  • 2014. CD11c+ dendritic cells rather than Langerhans cells are reduced in normal skin of immunosuppressed renal transplant recipients. Acta Dermato-Venereologica. 173-178.
  • 2013. Preeclampsia in healthy women and endothelial dysfunction 10 years later. American Journal of Obstetrics and Gynecology. 569.e1-569.e10.
  • 2013. Preeclampsia and prevalence of microalbuminuria 10 years later. American Society of Nephrology. Clinical Journal. 1126-1134.
  • 2013. Mortality in patients with IgA nephropathy. American Journal of Kidney Diseases. 883-890.
  • 2013. Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. Journal of the American Society of Nephrology. 137-148.
  • 2012. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. American Society of Nephrology. Clinical Journal. 1591-1597.
  • 2012. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrology, Dialysis and Transplantation. 1042-1049.
  • 2012. Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. JIMD Reports.
  • 2011. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney International. 663-670.
  • 2011. Laboratory investigation and follow-up of chronic kidney disease stage 3 in primary care. Clinica Chimica Acta. 1138-1142.
  • 2010. Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrology, Dialysis and Transplantation. 2168-2177.
  • 2010. Phenotypic Variation in a Large Family with Autosomal Dominant Hypocalcaemia. Hypertension in Pregnancy. 399-405.
  • 2010. Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. Nephrology, Dialysis and Transplantation. 1507-1513.
  • 2010. Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. European Journal of Clinical Investigation. 1104-1112.
  • 2009. The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. Clinical Nephrology. 118-124.
  • 2009. Nephrogenic systemic fibrosis and use of MR contrast media. Tidsskrift for Den norske legeforening. 180-182.
  • 2009. Monitoring renal Function in Fabry children: comparisons of measured and creatinine-based estimated Glomerular Filtration Rate. Nephrology, Dialysis and Transplantation. 7 pages.
  • 2008. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. American Journal of Kidney Diseases. 767-776.
  • 2008. En kvinne med kronisk nyresvikt, progredierende hudforkalkninger og sepsis. Tidsskrift for Den norske legeforening.
  • 2007. Long-term risk of cancer in membranous nephropathy patients. American Journal of Kidney Diseases. 396-403.
  • 2005. Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. Clinical Nephrology. 394-401.
  • 2005. Critical renal artery stenoses may cause a spectrum of cardiorenal failure and associated thromboembolic events. Clinical Nephrology. 487-492.
  • 2004. Bedside stereomicroscopy of renal biopsies may lead to a rapid diagnosis of Fabry's disease. Nephrology, Dialysis and Transplantation. 3202-3203.
  • 2003. C2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation. 1236-1238.
  • 2002. Effect of light excercise on renal hemodynamics in patients with hypertension and chronic renal disease. Scandinavian Journal of Urology and Nephrology. 464-473.
  • 2001. Sympathetic nervous system overactivity in hypertensive patients with chronic renal failure. Role of upright body position. Scandinavian Journal of Urology and Nephrology. 393-400.
  • 2001. Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus. Kidney and Blood Pressure Research. 64-70.
  • 2001. Akutt nyresvikt, nyrearteriestenose og angiotensinkonvertase (ACE)-hemmer. Tidsskrift for Den norske legeforening. 1784-1788.
  • 2001. Akutt dialysebehandling ved Haukeland Sykehus i 1999. Tidsskrift for Den norske legeforening. 1774-1779.
Academic lecture
  • 2019. Fabry Nephropathy: First mRNA-seq Findings from Kidney Biopsies Before and After Enzyme Replacement Therapy.
  • 2013. Podocytes: Therapeutic Target in Fabry Disease?
  • 2010. 5 YEARS FOLLOW-UP RENAL BIOPSIES IN PAEDIATRIC AND ADULT FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY.
  • 2009. Corneal changes in Fabry's disease.
  • 2001. Ultralyd og Doppler av nyrer.
  • 2001. Akutt nyresvikt, epidemiologi og nyreerstattende behandling.
  • 2001. Akutt nyresvikt (forekomst, diagnostikk, dialyseindikasjon).
  • 2001. ACE-hemmere og nyresvikt.
Editorial
  • 2011. A Mother and Daughter with Unexplained Renal Failure. Nephron. C1-C9.
Reader opinion piece
  • 2013. Week-to-Week Biological Variation in the N-terminal Prohormone of Brain Natriuretic Peptide in Hemodialysis Patients and Healthy Individuals. Clinical Chemistry. 1813-1814.
  • 2012. En mann i 50-årene med feber, hoste og anuri. Tidsskrift for Den norske legeforening. 1621-1624.
  • 2012. En kvinne i 50-årene med smerter i beina og nyresvikt. Tidsskrift for Den norske legeforening. 960-961.
  • 2011. Fabry or not Fabry – a question of ascertainment. European Journal of Human Genetics. 1111-1112.
  • 2002. Renal artery thrombosis with acute renal failure after withdrawal of angiotensin converting enzyme inhibitor: a case report. Nephrology, Dialysis and Transplantation. 687-689.
Letter to the editor
  • 2015. Renal failure due to excessive intake of almonds in the absence of Oxalobacter Formigenes. American Journal of Medicine. e29-e30.
  • 2015. Renal Failure due to Excessive Intake of Almonds in the Absence of Oxalobacter formigenes. American Journal of Medicine.
  • 2004. Renal artery thrombosis and acute renal failure after ACE inhibition. Nephrology, Dialysis and Transplantation. 565.
Doctoral dissertation
  • 2001. Renal hemodynamics in ambulatory patients with chronic renal disease. -.
Academic chapter/article/Conference paper
  • 2009. Ultralydveiledet biopsi og annen intervensjon. 4 pages.
  • 2009. Ultralyd av nyrer og urinveier. 12 pages.
Abstract
  • 2013. Renal structural-functional relationship (SFR) studies suggest that podocyte GL-3 accumulation predicts urine protein creatinine ratio in Fabry disease (FD) nephropathy (FDN). Molecular Genetics and Metabolism. S68-S69.
  • 2012. VALIDATION OF FRENCH MODEL TO PREDICT ESRD AND DEATH IN IGA NEPHROPATHY PATIENTS. Nephrology, Dialysis and Transplantation. 189-190.
  • 2012. STANDARDIZED MORTALITY RATE IN IGA NEPHROPATHY PATIENTS. Nephrology, Dialysis and Transplantation. 188-188.
  • 2012. OUTCOME IN BIOPSY-PROVEN LUPUS NEPHRITIS. Nephrology, Dialysis and Transplantation. 182-182.
  • 2012. Mosaicism of Podocyte Involvement in Untreated Females with Fabry Disease. Molecular Genetics and Metabolism. S47-S48.
  • 2010. The Potential Importance of Renal Biopsies in Early Management Decisions in Young Fabry Patients. Clinical Therapeutics. S97-S98.
  • 2010. SCORING SYSTEM FOR RENAL PATHOLOGY IN FABRY DISEASE: REPORT OF THE INTERNATIONAL STUDY GROUP OF FABRY NEPHROPATHY (ISGFN). Clinical Therapeutics. S105-S105.
  • 2010. RENAL FOLLOW-UP BIOPSIES IN YOUNG MALE FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. Clinical Therapeutics. S105-S107.
  • 2010. Natural history and structural-functional relationships (SFR) in Fabry nephropathy (FN). Molecular Genetics and Metabolism. S27-S28.
  • 2009. Monitoring renal Function in Fabry children; estimated or measured glomerular Filtration rate? Molecular Genetics and Metabolism. 74-75.
  • 2009. Fabry Disease: Unusual Symptoms in two Boys Treated with Lamotrigine and Fabrazyme, Respectively. Clinical Therapeutics. S43-S43.
  • 2008. Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with Fabry disease and microalbuminuria. Clinical Therapeutics. S42-S42.
Poster
  • 2019. Clinical Consequences of Paired Cardiac and Kidney Biopsies in a Treatment Naive Female Fabry Patient with a Classical Mutation and Minor Clnical Symptoms.
  • 2019. Accumulation of Globotriaosylceramide in Podocytes (PC) in Fabry Nephropathy Is Associated with Progressive PC Loss.
  • 2018. SINGLE INTRAVENOUS ACCESS FOR MEASUREMENT OF GLOMERULAR FILTRATION RATE IN CHILDREN AFTER MARKER INJECTION.
  • 2018. Podocyte structural parameters predict glomerular filtration rate (GFR) loss in male patients with classic Fabry disease.
  • 2018. IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR.
  • 2018. Fabry nephropathy: Transcriptome sequencing of microdissected renal compartments from archival kidney biopsies at baseline, and after 5 & 10 years of enzyme replacement therapy.
  • 2017. Single-point iohexol plasma clearance in children: validation of multiple formulas and sampling times.
  • 2017. Simplified Clinical Pre-histologic Scoring Method of Kidney Biopsies in Fabry Disease.
  • 2017. Podocyte globotriaosylceramide (GL-3) content strongly impacts age-dependent podocyte loss in ERT-naïve male Fabry patients.
  • 2016. Podocyte Hypertrophy and Globotriaosylceramide (GL-3) Accumulation Are Strong Predictors of Podocyte Loss in Enzyme Replacement Therapy Naïve Male Patients with Fabry Disease.
  • 2016. Differential response of glomerular parietal epithelial cells and podocytes to enzyme replacement therapy in Fabry nephropathy.
  • 2015. Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype .
  • 2015. LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) BENEFITS THE GLOMERULI MORE THAN THE VASCULATURE IN YOUNGER FABRY NEPHROPATHY .
  • 2015. FABRY DISEASE DIAGNOSED IN LIVING DONOR KIDNEY TRANSPLANT BIOPSY.
  • 2015. DIFFERENTIAL KIDNEY EFFECTS OF HIGH AND LOW ENZYME DOSE IN MALE SIBLINGS TREATED FOR 13 YEARS .
  • 2014. Renal Biopsies after 6-11 Years of Enzyme Replacement Therapy in 9 Young Classic Fabry Disease Patients.
  • 2014. Quantification of glomerular filtration rate (GFR) using a modelbased MR renography technique provides good agreement with IohexolGFR and eGFR in 20 healthy subjects. .
  • 2014. Five Children with Fabry Disease and Significant Tissue Damage in Renal Biopsies Despite Normal Clinical Renal Parameters.
  • 2014. Fabry nephropathy (FN) outcome and the impact of diagnostic kidney biopsies after 10 years enzyme replacement therapy (ERT).
  • 2014. Enzyme Replacement Therapy (ERT) in Fabry Disease (FD) Reduces Podocyte (PC) Globotriaosylceramide (GL3) Content within a Year (yr).
  • 2014. Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease.
  • 2013. Glomerular filtration rate (GFR) measured by iohexolclearance in children; how many sample points are necessary?
  • 2009. Renal follow-up biopsies in young male Fabry patients on enzyme replacement therapy.
  • 2008. Renal biopsies in children in Norway 1988-2005: clinical variables, complications and prognosis.
  • 2008. Formula GFR overestimates Renal Function in Children and Adult Males with Fabry Disease and Stage 1-2 CKD.
  • 2005. Glomerular and vascular changes are prominent in renal biopsies in children and adolescents with Fabry disease and microalbuminuria.
  • 2004. Early signs of focal and segmental glomerulosclerosis (FSGS) and arteriolopathy is prevalent in Fabry patients with minimal proteinuria or slightly reduced GFR.
  • 2001. Vitamin D, tartrate-resistent acid phosphatase 5B and osteocalcin in bone metabolism in patients undergoing hemodialysis (HD).
  • 2001. Vitamin D Resistant Acid Phosphatase 5B and Osteocalcin in Bone Metabolism in Patients (PTS) Undergoing Hemodialysis (HD).
  • 2001. Substatntial loss of 1.25 (OH)2 D3 in the urine in patients with nephrotic syndrome.
  • 2001. A simplified therapy regimen with epoetin alfa is sufficient in most HD-patients.
Errata
  • 2016. Erratum to: Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times (Pediatric Nephrology, (2017), 32, 2, (311-320), 10.1007/s00467-016-3436-z). Pediatric nephrology (Berlin, West). 375-376.
Academic literature review
  • 2013. Renal complications of Fabry disease in children. 679-687.
  • 2012. Assessment of Kidney Volumes From MRI: Acquisition and Segmentation Techniques. 1060-1069.
  • 2009. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. 1736-1743.
  • 2009. Nefrogen systemisk fibrose ved bruk av MR-kontrastmiddel. 180-182.
  • 2009. Kognitiv svikt ved terminal nyresykdom. 296-299.

More information in national current research information system (CRIStin)

Research groups